 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Predicting Risk for Prolonged High INR after Too Much Anticoagulation
18 September 2001 | Volume 135 Issue 6 | Page S37
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin." It is in the 18 September 2001 issue of Annals of Internal Medicine (volume 135, pages 393-400). The authors are EM Hylek, S Regan, AS Go, RA Hughes, DE Singer, and SJ Skates.
What is the problem and what is known about it so far?
Warfarin is a drug that "thins the blood" by interfering with normal blood clotting (anticoagulation). It is given to prevent blood clots in the legs, lungs, heart, and brain. Patients who take warfarin need routine blood tests to see whether their blood is "too thin," a condition that can cause serious bleeding. The test that best measures warfarin's actions is the international normalized ratio (INR). Patients with too much anticoagulation have high INRs and high risk for bleeding. If the INR is greater than 5.0, warfarin treatment is often stopped for several days, or vitamin K1 is given to counteract the effects of warfarin. However, vitamin K1 may be unnecessary in some patients, and it can cause adverse effects. Deciding which patients need vitamin K1 is not easy because it is difficult to know which patients will have prolonged abnormal INR values without vitamin K1 treatment.
Why did the researchers do this particular study?
To identify factors that predict prolonged high INR values after too much anticoagulation.
Who was studied?
633 patients who were treated in an anticoagulant therapy unit between 1993 and 1998.
How was the study done?
The researchers reviewed medical records of patients who had been followed in their clinic for more than 60 days. They identified patients whose INRs went above 6.0 at some point and who then had repeated INR tests after warfarin treatment had been stopped for 2 days. No patient had received vitamin K1. The researchers divided patients into those whose repeated INR tests suggested a prolonged risk (INR of 4.0 or greater) and those whose repeated tests no longer suggested such a risk (INR less than 4.0, a safer value).
What did the researchers find?
About one third of the patients had an INR of 4.0 or greater after warfarin treatment had been withheld for 2 days. Factors associated with a prolonged INR of 4.0 or greater were being older, having a higher INR when too much anticoagulation was first recognized, having unstable heart failure, having cancer that was metastatic or required chemotherapy, and needing small rather than large weekly doses of warfarin to maintain anticoagulation before the episode of too much anticoagulation.
What were the limitations of the study?
Study data were obtained from patients' records, which are sometimes incomplete. Although high INR is a marker for increased bleeding risk, many people with prolonged INRs of 4.0 or greater do not bleed. The study did not look at factors that predict actual bleeding.
What are the implications of the study?
Excessive anticoagulation is likely to last longest in patients who are older, have unstable heart failure or cancer, have higher INRs, and require smaller maintenance doses of warfarin. Reversal of too much anticoagulation with vitamin K1 should be considered for such patients.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, G. Filippatos, F. Flachskampf, R. Hall, B. Iung, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur. Heart J., January 26, 2007; (2007) ehl428v1. [Full Text] [PDF]
|
|
|
|
 |
|
 A.-H. Kristoffersen, G. Thue, and S. Sandberg Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare Clin. Chem., October 1, 2006; 52(10): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Shermock, J. T. Connor, N. T. Smith, J. M. Fink, and L. Bragg Validity of Criteria Used to Evaluate Fingerstick Devices That Assess International Normalized Ratio Med Decis Making, May 1, 2006; 26(3): 239 - 246. [Abstract] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. DeZee, W. T. Shimeall, K. M. Douglas, N. M. Shumway, and P. G. O'Malley Treatment of Excessive Anticoagulation With Phytonadione (Vitamin K): A Meta-analysis. Arch Intern Med, February 27, 2006; 166(4): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. McBride A Preliminary Assessment of the Critical Differences Between Novel Oral Anticoagulants Currently in Development J. Clin. Pharmacol., September 1, 2005; 45(9): 1004 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Elbe and S. W Chang Moxifloxacin-Warfarin Interaction: A Series of Five Case Reports Ann. Pharmacother., February 1, 2005; 39(2): 361 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Fang, Y. Chang, E. M. Hylek, J. Rosand, S. M. Greenberg, A. S. Go, and D. E. Singer Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation Ann Intern Med, November 16, 2004; 141(10): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, R. G. Hart, G. A. Wells, P. Petersen, P. J. Koudstaal, A. L. Gullov, B. S. P. Hellemons, B. G. Koefed, and A. Laupacis A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin Arch Intern Med, April 28, 2003; 163(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Predicting Sustained High INR After Excessive Warfarin Anticoagulation Journal Watch Cardiology, November 30, 2001; 2001(1130): 10 - 10. [Full Text]
|
|
|
|
 |
|
 Risk Factors for Prolonged Excessive Anticoagulation Journal Watch (General), October 2, 2001; 2001(1002): 3 - 3. [Full Text]
|
|
|
|
|
|
H. I. Bussey Managing Excessive Warfarin Anticoagulation Ann Intern Med, September 18, 2001; 135(6): 460 - 462. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
